IFM Therapeutics

Bristol-Myers Squibb to acquire IFM Therapeutics

Wednesday, August 9, 2017

Bristol-Myers Squibb and IFM Therapeutics (IFM) announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

[Read More]